Shares of blue-chip pharmaceutical company Merck (NYSE:MRK) have been clobbered (in big pharma terms) since reporting earnings on Friday. With the stock down more than 5% since that report, some investors might be looking to take action.

In the video below, health care bureau chief Brenton Flynn offers his opinion of Merck today, and whether investors should take the money and run -- or back up the truck and buy more.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.